将 Ridostin Pro 和 Poly(I:C) 作为增强抗肿瘤疫苗免疫原性的佐剂的研究

Q4 Medicine

Siberian journal of oncology Pub Date : 2024-07-04 DOI:10.21294/1814-4861-2024-23-3-86-99

A. V. Ponomarev, P. V. Tsarapaev, M. Baryshnikova, Z. A. Sokolova, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, E. Danilenko, V. Kosorukov

{"title":"将 Ridostin Pro 和 Poly(I:C) 作为增强抗肿瘤疫苗免疫原性的佐剂的研究","authors":"A. V. Ponomarev, P. V. Tsarapaev, M. Baryshnikova, Z. A. Sokolova, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, E. Danilenko, V. Kosorukov","doi":"10.21294/1814-4861-2024-23-3-86-99","DOIUrl":null,"url":null,"abstract":"Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. Material and Methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG 7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180–188 with the studied adjuvants was performed in a mixed (preventive/therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG 7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180–188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry. Results. In the B16-F10 model, vaccination in a mixed mode protected mice from tumor formation, and the mice lived for more than 100 days. For B16-F10 and EG 7, vaccination in the therapeutic mode led only to inhibition of tumor growth. Ridostin Pro and Poly(I:C) showed a similar ability to develop specific immunity to the peptide TRP2 and ovalbumin. Ridostin Pro increased cytokine levels in the blood serum of mice more strongly than Poly(I:C). Both drugs caused similar changes in the immunophenotype of spleen cells, but Ridostin Pro increased the number of CD 69+ T cells more strongly than Poly(I:C). Conclusion. The comparison of two drugs as adjuvants for antitumor vaccines showed that the domestic drug Ridostin Pro did not inferior in effectiveness to Poly(I:C) on mouse models. In this regard, Ridostin Pro can be considered as a promising adjuvant for antitumor vaccines and deserves further study.","PeriodicalId":21881,"journal":{"name":"Siberian journal of oncology","volume":" 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study of Ridostin Pro and Poly(I:C) as adjuvants that enhance the immunogenicity of an antitumor vaccine\",\"authors\":\"A. V. Ponomarev, P. V. Tsarapaev, M. Baryshnikova, Z. A. Sokolova, A. A. Rudakova, M. V. Mironova, D. V. Gusev, G. M. Levagina, E. Danilenko, V. Kosorukov\",\"doi\":\"10.21294/1814-4861-2024-23-3-86-99\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. Material and Methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG 7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180–188 with the studied adjuvants was performed in a mixed (preventive/therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG 7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180–188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry. Results. In the B16-F10 model, vaccination in a mixed mode protected mice from tumor formation, and the mice lived for more than 100 days. For B16-F10 and EG 7, vaccination in the therapeutic mode led only to inhibition of tumor growth. Ridostin Pro and Poly(I:C) showed a similar ability to develop specific immunity to the peptide TRP2 and ovalbumin. Ridostin Pro increased cytokine levels in the blood serum of mice more strongly than Poly(I:C). Both drugs caused similar changes in the immunophenotype of spleen cells, but Ridostin Pro increased the number of CD 69+ T cells more strongly than Poly(I:C). Conclusion. The comparison of two drugs as adjuvants for antitumor vaccines showed that the domestic drug Ridostin Pro did not inferior in effectiveness to Poly(I:C) on mouse models. In this regard, Ridostin Pro can be considered as a promising adjuvant for antitumor vaccines and deserves further study.\",\"PeriodicalId\":21881,\"journal\":{\"name\":\"Siberian journal of oncology\",\"volume\":\" 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Siberian journal of oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21294/1814-4861-2024-23-3-86-99\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Siberian journal of oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21294/1814-4861-2024-23-3-86-99","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

研究目的：比较抗原相同但佐剂不同的疫苗的抗肿瘤效力和免疫原性：Ridostin Pro或Poly(I:C)；评估Ridostin Pro和Poly(I:C)对血清细胞因子谱和小鼠脾脏细胞免疫表型的影响。材料与方法为了评估使用不同佐剂的疫苗的抗肿瘤效果，我们使用了两种可移植的肿瘤株：黑色素瘤 B16-F10 和 C57BL/6 小鼠的 EG 7-OVA 淋巴瘤（表达卵清蛋白）。针对黑色素瘤 B16-F10，在混合（预防/治疗）和治疗方案中使用多肽 TRP2 180-188 和所研究的佐剂进行接种。含佐剂的卵清蛋白以治疗模式接种 EG 7 淋巴瘤。使用 ELISPOT 方法评估了不同佐剂的疫苗在无肿瘤小鼠体内的免疫原性。在这种情况下，多肽 TRP2 180-188 和蛋白卵清蛋白也可作为抗原。使用流式细胞术研究了血清中细胞因子的分布情况以及小鼠脾脏细胞在服用 Ridostin Pro 或 Poly(I:C) 后免疫表型的变化。结果显示在B16-F10模型中，混合模式的疫苗接种保护小鼠免于肿瘤形成，小鼠存活时间超过100天。对于 B16-F10 和 EG 7，以治疗模式接种疫苗只能抑制肿瘤生长。Ridostin Pro 和 Poly(I:C) 对多肽 TRP2 和卵清蛋白产生特异性免疫的能力相似。Ridostin Pro比Poly(I:C)更能提高小鼠血清中的细胞因子水平。这两种药物对脾脏细胞免疫表型的改变相似，但利多司汀 Pro 对 CD 69+ T 细胞数量的增加作用比聚(I:C)更强。结论两种药物作为抗肿瘤疫苗佐剂的比较结果表明，国产药物 Ridostin Pro 在小鼠模型上的效果并不逊色于 Poly(I:C)。因此，Ridostin Pro 可被视为一种很有前景的抗肿瘤疫苗佐剂，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Study of Ridostin Pro and Poly(I:C) as adjuvants that enhance the immunogenicity of an antitumor vaccine

Aim of the study: to compare the antitumor efficacy and immunogenicity of vaccines with the same antigens but different adjuvants: Ridostin Pro or Poly(I:C); to evaluate the effect of Ridostin Pro and Poly(I:C) on the cytokine profile of serum and the immunophenotype of mouse spleen cells. Material and Methods. To evaluate the antitumor efficacy of vaccines with different adjuvants, two transplantable tumor lines were used: melanoma B16-F10 and EG 7-OVA lymphoma (expressing ovalbumin) for C57BL/6 mice. Against melanoma B16-F10, vaccination with the peptide TRP2 180–188 with the studied adjuvants was performed in a mixed (preventive/therapeutic) and therapeutic regimens. Ovalbumin with adjuvants was vaccinated against EG 7 lymphoma in a therapeutic mode. The immunogenicity of vaccines with different adjuvants in mice without tumors was evaluated by the ELISPOT method. In this case, the peptide TRP2 180–188 and the protein ovalbumin also served as antigens. The cytokine profile of blood serum and changes in the immunophenotype of mouse spleen cells after administration of Ridostin Pro or Poly(I:C) were studied using flow cytometry. Results. In the B16-F10 model, vaccination in a mixed mode protected mice from tumor formation, and the mice lived for more than 100 days. For B16-F10 and EG 7, vaccination in the therapeutic mode led only to inhibition of tumor growth. Ridostin Pro and Poly(I:C) showed a similar ability to develop specific immunity to the peptide TRP2 and ovalbumin. Ridostin Pro increased cytokine levels in the blood serum of mice more strongly than Poly(I:C). Both drugs caused similar changes in the immunophenotype of spleen cells, but Ridostin Pro increased the number of CD 69+ T cells more strongly than Poly(I:C). Conclusion. The comparison of two drugs as adjuvants for antitumor vaccines showed that the domestic drug Ridostin Pro did not inferior in effectiveness to Poly(I:C) on mouse models. In this regard, Ridostin Pro can be considered as a promising adjuvant for antitumor vaccines and deserves further study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Siberian journal of oncology Medicine-Oncology

CiteScore

0.40

自引率

0.00%

发文量

117

审稿时长

8 weeks

期刊介绍： The main objectives of the journal are: -to promote the establishment of Russia’s leading worldwide positions in the field of experimental and clinical oncology- to create the international discussion platform intended to cover all aspects of basic and clinical cancer research, including carcinogenesis, molecular biology, epidemiology, cancer prevention, diagnosis and multimodality treatment (surgery, chemotherapy, radiation therapy, hormone therapy), anesthetic management, medical and social rehabilitation, palliative care as well as the improvement of life quality of cancer patients- to encourage promising young scientists to be actively involved in cancer research programs- to provide a platform for researches and doctors all over the world to promote, share, and discuss various new issues and developments in cancer related problems. (to create a communication platform for the expansion of cooperation between Russian and foreign professional associations).- to provide the information about the latest worldwide achievements in different fields of oncology The most important tasks of the journal are: -to encourage scientists to publish their research results- to offer a forum for active discussion on topics of major interest - to invite the most prominent Russian and foreign authors to share their latest research findings with cancer research community- to promote the exchange of research information, clinical experience, current trends and the recent developments in the field of oncology as well as to review interesting cases encountered by colleagues all over the world- to expand the editorial board and reviewers with the involvement of well-known Russian and foreign experts- to provide open access to full text articles- to include the journal into the international database- to increase the journal’s impact factor- to promote the journal to the International and Russian markets